^
Association details:
| Biomarker: | IGF2 overexpression |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug: | xentuzumab (BI-836845) (IGF-2 inhibitor, IGF1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Identification of IGF2 as genomic driver and actionable therapeutic target in hepatoblastoma
Excerpt:
Xentuzumab, a monoclonal antibody against IGF2, significantly reduced proliferation and clonogenic capacity in IGF2-high HB cell lines, whereas in combination with cisplatin in an IGF2-high organoid model was able to increase cisplatin efficacy by 25-fold and promote apoptosis. In vivo, xentuzumab + cisplatin reduced viable tumor volume and extended time to sacrifice (1500 mm3) compared to cisplatin alone (p = 0.04).
Source:
Title:
Identification of IGF2 as genomic driver and actionable therapeutic target in hepatoblastoma
Excerpt:
Xentuzumab, a monoclonal antibody against IGF2, significantly reduced proliferation and clonogenic capacity in IGF2-high HB cell lines, whereas in combination with cisplatin in an IGF2-high organoid model was able to increase cisplatin efficacy by 25-fold and promote apoptosis. In vivo, xentuzumab + cisplatin reduced viable tumor volume and extended time to sacrifice (1500 mm3) compared to cisplatin alone (p = 0.04).
Secondary therapy:
cisplatin
